Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
TOKYO, OCTOBER 19, 2020 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, PhD, “Astellas”) today announced that in collaboration with FibroGen and AstraZeneca, 42 roxadustat abstracts will be presented at the American Society...
TOKYO and Berkeley, CA., October 15, 2020 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Iota Biosciences, Inc. (Co-founders and Co-CEOs: Michel Maharbiz, Ph.D. and Jose Carmena, Ph.D., “iota”) announced today...
TOKYO and BOTHELL, Wash. -- October 12, 2020 -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Seagen Inc. (Nasdaq:SGEN) today announced positive topline results from the second cohort of patients in the pivotal phase...
TOKYO, September 28, 2020 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced findings from two Real-World Evidence (RWE) studies and a qualitative sleep survey that underscore the prevalence of...
TOKYO and PITTSBURGH, PA, September 24, 2020 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and University of Pittsburgh (Chancellor: Patrick Gallagher, Ph.D., “Pittsburgh”) have entered into a research collaboration...
TOKYO, September 23, 2020 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) has signed an agreement with two research centers at the University of Tokyo (President: Makoto Gonokami, Ph.D.): The Institute for Life Science...
Read more about Astellas Collaborates with Two Research Centers at the University of Tokyo
TOKYO and BOTHELL, Wash. -- September 18, 2020 -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that a phase 3 trial of PADCEV® (enfortumab vedotin-ejfv)...
TOKYO, August 24, 2020 - Astellas Pharma Inc. (Tokyo, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) announced today that it will start accepting advance applications and taking reservations for its exercise support service Fit-eNce®1, which encourages...
TOKYO, July 22, 2020 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced it has been awarded a grant from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH)...
TOKYO, July 20, 2020 – Astellas Pharma Inc. (President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that it has been named to the FTSE4Good Index Series for ninth consecutive year. Astellas was recognized for its strong performance especially...
Read more about Astellas Named to FTSE4Good Index Series for Ninth Consecutive Year
Follow us
